BioSpace News Archive

Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system and related pathways, announced today that it will be participating in two upcoming virtual conferences. Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences, will be speaking on a panel entitled, “Disruptive Thinking: What’s Next for Pain,” at BIO Digital being

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,317,074 shares of the Company’s common stock, at a purchase pr

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the virtual Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 . Richard A. Gonzalez , chairman and chief executive officer, AbbVie, will present at 9:30 a.m. Central time . A live audio webcast of t

Align Technology, Inc. announced that the company is scheduled to speak at upcoming financial conferences.

Fractyl Laboratories Inc. ( Fractyl ) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) to begin a pi

Novellus, a precision-oncology drug development company, announced today that it has entered into an exclusive worldwide license agreement with Plexxikon, a member of the Daiichi Sankyo Group, for PLX8394, its clinical-stage oncology drug candidate which targets the BRAF protein. PLX8394 is currently completing a Ph

Herzing University, an accredited, private nonprofit institution, announced an RN to MSN program that’s designed for registered nurses who want to further their career with a Master of Science in Nursing degree.

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that the Neovasc Reducer™ device

Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of COVID-19.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Diana McKenzie has been appointed to its board of directors as an independent director. Ms. McKenzie is a senior technology leader and innovator with deep experience across pharma, biotechnology and technology. She most recently served as Chief Information Officer of Workday, Inc., a cloud-based financial and human capital management software company. Prior